Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BG-C9074

Antibody-drug conjugate · Kills target cells, directed at B7-H4 (VTCN1) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer

What is BG-C9074?

BG-C9074 is an antibody-drug conjugate that pairs a monoclonal antibody against B7-H4 (VTCN1), a B7 family immune modulator upregulated on tumor cells and tumor-associated macrophages, with a cytotoxic payload. After binding and internalization, the payload causes apoptosis in B7-H4-expressing cells. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
B7-H4 (VTCN1)
Mechanism
Kills target cells, directed at B7-H4 (VTCN1)
Pathways
apoptosis
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid Tumor

Other drugs acting on VTCN1

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BG-C9074

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.